Serum Scores A Double - HPV Vaccine In India, Novavax Vaccine In US
Demand High For HPV, Low For COVID-19 Vaccine
Serum Institute will supply initial doses of NVX-CoV2373 in the US, but late approvals have meant Novavax's vaccine is facing weak demand and surplus stocks in other parts of the world. Meanwhile, Serum has also secured a nod in India for the first indigenously-developed HPV vaccine, also the fifth globally.
You may also be interested in...
Dr Patti Gravitt, Deputy Director, Center for Global Health, US National Cancer Institute, in an interview with Scrip, discusses a range of strategies underway and proposed to strengthen cancer control efforts in the Asia Pacific. HPV vaccination and a regional cancer control dashboard are among the areas she highlighted.
Gains from its COVID-19 vaccine made Serum Institute’s founder the world’s richest healthcare billionaire. But the demand for boosters hasn’t materialized as expected, leading to a deal with Biocon being tweaked. Meanwhile, gains from India’s first indigenously-developed HPV vaccine and Oxford-partnered malaria vaccine seem imminent.
HPV vaccines have come a long way since their launch in 2006, though not without their share of bumps and misinformation campaigns. US pediatric infectious disease specialist, Dr Kenneth Alexander, talks to Scrip about how data has evolved, why the US may not be the best example to emulate for HPV vaccination and new products on the horizon, among other topics.